
Deltawave builds technology to run the complete design process for small molecules and biologics. Their open-source technology is designed for autonomous science, automating complex workflows with human oversight. They integrate techniques like test time compute scaling and reinforcement learning within a modular and scalable framework. Their EVE system orchestrates these methods in a multi-agent, multi-turn, multi-model system, allowing users to steer and intervene in processes for adaptability and efficiency across diverse scientific applications.

Deltawave builds technology to run the complete design process for small molecules and biologics. Their open-source technology is designed for autonomous science, automating complex workflows with human oversight. They integrate techniques like test time compute scaling and reinforcement learning within a modular and scalable framework. Their EVE system orchestrates these methods in a multi-agent, multi-turn, multi-model system, allowing users to steer and intervene in processes for adaptability and efficiency across diverse scientific applications.
Headquarters: Paris, France
Product: EVE — autonomous AI OS for molecular design and R&D
Founded: 2023 (launched) / 2024 (registered year listed)
Stage / Funding: Pre-seed (May 6, 2024); investor: Antler
Team size (reported): About 5 employees
Autonomous molecular discovery and R&D workflow automation for chemistry and biology.
2024
Biotechnology
161,558 USD
“Antler listed as an investor in the May 2024 pre-seed round”